These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 3477662

  • 1. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
    Ono K, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546
    [Abstract] [Full Text] [Related]

  • 3. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 4. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
    Miller AC, Henderson BW.
    J Natl Cancer Inst; 1986 Aug 15; 77(2):505-10. PubMed ID: 3461211
    [Abstract] [Full Text] [Related]

  • 5. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988 May 01; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 7. Effect of treatment duration and glutathione depletion on mitomycin C cytotoxicity in vitro.
    Perry RR, Greaves BR, Rasberry U, Barranco SC.
    Cancer Res; 1992 Sep 01; 52(17):4608-12. PubMed ID: 1511428
    [Abstract] [Full Text] [Related]

  • 8. Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
    Ono K, Komuro C, Tsutsui K, Shibamoto Y, Nishidai T, Takahashi M, Abe M, Shrieve DC.
    Br J Cancer; 1986 Nov 01; 54(5):749-54. PubMed ID: 3801271
    [Abstract] [Full Text] [Related]

  • 9. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G, Zeller WJ.
    Anticancer Res; 1991 Nov 01; 11(6):2231-7. PubMed ID: 1776864
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 11. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH, Gupta V, Singh SV.
    Arch Biochem Biophys; 1994 Jan 01; 308(1):164-70. PubMed ID: 8311448
    [Abstract] [Full Text] [Related]

  • 12. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC, Denekamp J, Minchinton AI.
    Radiat Res; 1985 Jun 01; 102(3):283-94. PubMed ID: 4070545
    [Abstract] [Full Text] [Related]

  • 13. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 14. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 01; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 15. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U, Schorn H.
    Radiat Res; 1986 Mar 01; 105(3):351-69. PubMed ID: 3754339
    [Abstract] [Full Text] [Related]

  • 16. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS.
    Cancer Res; 1988 May 15; 48(10):2764-7. PubMed ID: 3359437
    [Abstract] [Full Text] [Related]

  • 17. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH, Singh SV.
    Cancer Res; 1992 Dec 01; 52(23):6666-70. PubMed ID: 1423311
    [Abstract] [Full Text] [Related]

  • 18. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 19. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
    Soble MJ, Dorr RT.
    Res Commun Chem Pathol Pharmacol; 1987 Feb 01; 55(2):161-80. PubMed ID: 3823607
    [Abstract] [Full Text] [Related]

  • 20. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Feb 01; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.